

Reference Number: FOI2021/442
From: Private Individual
Date: 21 January 2022
Subject: Policies for Major haemorrhaging in hospital

Q1 Following the publication of the NICE Pathway 'Major haemorrhaging in hospital' in May 2021, I am writing to enquire if Liverpool Heart and Chest NHS Foundation Trust has protocols in place for the management of major haemorrhage, the rapid identification of patients taking anticoagulants and the reversal of anticoagulation agents. If such protocols are available, please could I request a copy.

Does your organisation have a specific policy for the emergency reversal of anticoagulation? Or is this handled as part of your major haemorrhage protocol.

A1 Yes, the management of bleeding is in the trust's anticoagulation policy. This also contains the NW regional transfusion committee's management of massive haemorrhage toolkit.

Please see the attached policy document, which covers all of the above: *Anticoagulation v7.0*

Anticoagulation Policy

Policy

| | | | |
|---|--|-----------------|------------|
| For completion by Author | | | |
| Author(s) Name and Title: | Dr D Gupta, Consultant Cardiologist, Danny Forrest, Chief Pharmacist, Mr M Poullis, Consultant Cardiothoracic Surgeon, Dr J Morris, Consultant Cardiologist, Dr M Desmond, Consultant Anaesthetist, Mr M Vincent, Deputy Chief Pharmacist | | |
| Scope: | This policy applies to all clinical staff (including temporary staff) working within LHCH who are involved in the prescribing, dispensing and administration of anticoagulants, whether parenteral or oral. This policy also applies to staff involved in the discharge of patients to ensure that sufficient information is sent with the patient to enable the safe continuation of their anticoagulation therapy. | Classification: | Clinical |
| Version Number: | 7.0 | Review Date: | 10/03/2022 |
| Replaces: | 6.4 | | |
| To be read in conjunction with the following documents: | The Medicines Policy, Medicines Administration Procedure, HITT Policy, Prevention of VTE Policy, Use of Enoxaparin in PCI, Guidelines for anticoagulation before, during and after EP Procedures. | | |
| Document for public display: | Yes | | |
| Executive Lead | Dr Raph Perry | | |

| | | | |
|--|---------------------|---------------------|------------|
| For completion by Approving Committee | | | |
| Equality Impact Analysis Completed: | | No | |
| Endorsement Completed: | Yes | Record of Changes | No |
| Authorised by: | Drug & Therapeutics | Authorisation date: | 20/10/2021 |

| | | | | | |
|---|-------------------------------------|---------------|------------------------|-------------|------------|
| For completion by Document Control | | | | | |
| Unique ID No: | TC21(08) | Issue Status: | Approved | Issue Date: | 29/10/2021 |
| After this document is withdrawn from use it must be kept in archive for the lifetime of the Trust, plus 6 years. | | | | | |
| Archive: | Document Control | | Date Added to Archive: | | |
| Officer responsible for Archive: | IG and Document Control Facilitator | | | | |

Contents

| | |
|---------------------------------------|----|
| Document Statement | 3 |
| 1. Roles and Responsibilities | 3 |
| 2. Controlled Document Standards..... | 3 |
| 3. Procedure..... | 3 |
| 4. Policy Implementation Plan | 16 |
| 5. Monitoring of Compliance..... | 17 |
| 6. Expert Advice | 17 |
| 7. References..... | 17 |
| 8. Appendices | 18 |
| 9. Endorsed By:..... | 35 |
| 10. Record of Changes | 36 |

Document Statement

This Anticoagulation Policy is designed to ensure that the initiation and maintenance of anticoagulation therapy is conducted in a safe and efficacious manner. The policy covers the initiation of therapy within LHCH and the onward dissemination of information concerning the anticoagulation therapy of our patients to their base hospital, General Practitioner or anticoagulation clinic.

1. Roles and Responsibilities

Medical Director

The above Director is responsible for implementation of this policy.

The Drug and Therapeutics Committee

The above Committee is responsible for development and approval of this policy.

Liverpool Heart and Chest Hospital NHS Trust Staff are responsible for co-operating with the development and implementation of Corporate policies as part of their normal duties and responsibilities.

Temporary or Agency Staff, Contractors, Students or Others will be expected to comply with the requirements of all Trust policies applicable to their area of operation.

Medical staff will be responsible for the prescribing of anticoagulation therapy, both parenteral and oral, using the LHCH in-patient or out-patient prescriptions appropriately (the Electronic Prescribing System should be used for all in-patient prescribing including intravenous continuous therapy).

Nursing staff will be responsible for administration of anticoagulation therapy in accordance with the Medicines Policy. Nursing staff will also be responsible for the onward communication of anticoagulation information regarding their patients and for ensuring that a monitoring appointment is arranged prior to discharge for patients on Vitamin K antagonists. If transport is required for the patient to achieve their first monitoring appointment this should be arranged before the patient leaves the ward or clinic area.

Pharmacists will be responsible for ensuring that all patients starting long-term anticoagulation therapy are counselled appropriately and that this is documented in their EPR record.

2. Controlled Document Standards

All staff involved with anticoagulation will be expected to comply with current legislation e.g. Medicines Act 1968 and the trust's Medicines Policy, together with their code of professional practice ensuring safety of patients and other staff at all times.

3. Procedure

Liverpool Heart and Chest hospital NHS Trust aims to ensure that all patients for whom anticoagulation therapy is deemed appropriate will be effectively managed while in the Trust and

| | | |
|--------------------------------|--|--------------|
| Version No 7.0 October 2021 | Anticoagulation Current version is held on the Intranet Check with Intranet that this printed copy is the latest issue | Page 3 of 36 |
|--------------------------------|--|--------------|

that their clinical details and supervision of their oral maintenance therapy will be transferred to an appropriate organisation. This policy covers both parenteral and oral anticoagulation.

3.1 DEFINITIONS

ACT - The activated clotting time. A measure of heparin activity that can be performed as a near-patient test.

APTT – The partial thromboplastin time (PTT) or activated partial thromboplastin time (aPTT or APTT) is a performance indicator measuring the efficacy of both the “intrinsic” (now referred to as the contact activation) pathway and the common coagulation pathways. The APTT is used to detect abnormalities in blood clotting and a ratio of patient’s APTT against a laboratory APTT range is used to monitor the treatment effects with heparin, a major anticoagulant.

INR – International Normalised Ratio, a system established by the World Health Organisation (WHO) and the International Committee on Thrombosis and Haemostasis for reporting the results of blood coagulation (clotting) tests. All results are standardised using the international sensitivity index for the particular thromboplastin reagent and instrument combination utilized to perform the test. For example, a person taking the anticoagulant warfarin might optimally maintain a prothrombin time (pro time, or, PT) of 2 to 3 INR. No matter which laboratory checks the prothrombin time the result should be the same.

DOACs – non-vitamin K oral anticoagulation agents – four newer agents which differ in many ways from warfarin, including rapid onset of action, shorter half-life, fewer drug-drug or drug-food interactions, lack of a need for monitoring or dose titration / adjustment. Dabigatran is the only agent which currently has a reversal agent.. These drugs have limited licensed indications.

PCC – Prothrombin complex concentrate (Octaplex) contains all four vitamin K-dependent coagulation factors (II, VII, IX and X) and the thrombo-inhibitor proteins C and S. It is used to rapidly replenish deficient levels of circulating clotting factors more effectively than fresh frozen plasma in life-threatening bleeding situations.

3.2 CLINICAL CONDITIONS WHICH MAY REQUIRE ANTICOAGULATION

The following is a list of conditions which may occur within LHCH practice and require anticoagulation; however, this list is not exhaustive. The anticoagulation of some of these conditions may not be within the scope of this policy, however, other policies within the Trust exist for their treatment.

For LHCH the following patients may require oral and / or parenteral anticoagulation therapy:

- Prevention of thrombo-embolism for patients with atrial fibrillation (see below)
- Treatment of deep vein thrombosis or pulmonary embolism (see below)
- Following coronary endarterectomy (refer to consultant or SPR)
- Patients with a left ventricular aneurysm / thrombus (refer to consultant or SPR)
- Following valve surgery (dependent upon the patient, whether mechanical or tissue valve and the position of the valve – refer to consultant)
- Following pulmonary vein isolation (PVI) (see below)
- DC cardioversion for atrial fibrillation/flutter
- Acute Coronary Syndrome (see below)
- Prophylaxis of deep vein thrombosis in surgical patients (see below)
- Prophylaxis of deep vein thrombosis in medical patients (see below)

Other clinical conditions may require anticoagulation therapy; for example:

Cardiopulmonary bypass patients – see procedure from perfusion department

Off-pump bypass patients

Anticoagulation therapy for renal replacement therapy – see policy within Critical care

| | | |
|--------------------------------|--|--------------|
| Version No 7.0 October 2021 | Anticoagulation Current version is held on the Intranet Check with Intranet that this printed copy is the latest issue | Page 4 of 36 |
|--------------------------------|--|--------------|

Lupus anticoagulant, anticardiolipin antibodies, pregnancy, liver disease and deficiencies of clotting factors – refer to haematologist for advice.

Other electrophysiological procedures – refer to Trust policy “Guidelines for anticoagulation before, during and after EP procedures”

Women with mechanical heart valves considering or planning pregnancy should be referred to a consultant with a specialist interest to plan anticoagulation during pregnancy.

3.3 HEPARIN (UNFRACTIONATED) OR LOW MOLECULAR WEIGHT HEPARIN* THERAPY

3.3.1 Treatment of Pulmonary Embolism or Deep Vein Thrombosis

- **Unfractionated Heparin Infusion Guidelines**

These are contained within LHCH Drug Formulary; however, they are shown in Appendix 3 for completeness. These guidelines should be applicable whether the patient has been previously anticoagulated or not.

- **Low Molecular Weight Heparin***

The LMWH of choice for treatment of VTE is Enoxaparin. Enoxaparin can be administered SC either as 1.5 mg/kg once daily or 1mg/kg twice daily. The dose regimen of 1.5 mg/kg once daily should be used in uncomplicated patients with low risk of VTE recurrence. The dose regimen of 1 mg/kg twice daily should be used in all other patients such as those with obesity, with symptomatic PE, cancer, recurrent VTE or proximal (vena iliac) thrombosis. The patient's weight must be measured prior to commencement of therapy and rechecked at regular intervals during their treatment e.g. alternate days. The patient's creatinine clearance should also be monitored daily while on LMWH and the dose adjusted accordingly (for example, for patients with creatinine clearance less than 30ml/min, the dose should be adjusted to 1mg/kg/day). Appendix eight contains guidance tables for prescribing enoxaparin. It is recommended that the prescriber should choose between using the 120mg or the 150mg syringe, where the graduation marks represent 3mg each.

3.3.2 Treatment of Acute Coronary Syndrome (ACS)

The LMWH of choice for treatment of ACS is Enoxaparin at a dose of 1mg/kg twice a day. Enoxaparin is usually stopped 12 hours before percutaneous coronary intervention (PCI). The patient's creatinine clearance should also be monitored daily while on LMWH and the dose adjusted accordingly (for example, for patients with creatinine clearance less than 30ml/min, the dose should be adjusted to 1mg/kg ONCE daily). Fondaparinux is also licensed for the treatment of unstable angina (UA) or non-ST segment elevation myocardial infarction (NSTEMI). It is administered by subcutaneous injection at a dose of 2.5mg once daily, regardless of body weight. Patient's renal function should be monitored, however, and the drug should be avoided if the eGFR is less than 20 ml / minute. Fondaparinux is usually stopped 24 hours before PCI. It is not currently initiated at LHCH.

3.3.3 Prevention of thrombo-embolism for patients with atrial fibrillation

The LMWH of choice for prevention of thromboembolism in patients with AF is Enoxaparin at a dose of 1.5mg/kg once daily. The patient's creatinine clearance should be monitored daily while on LMWH and the dose reduced to 1mg/kg ONCE daily if creatinine clearance is less than 30ml/min. Enoxaparin may be used whilst concurrent oral anticoagulation with warfarin is commenced and until INR is above 2.0 (see below). New oral anticoagulation agents do not

| | | |
|--------------------------------|--|--------------|
| Version No 7.0 October 2021 | Anticoagulation Current version is held on the Intranet Check with Intranet that this printed copy is the latest issue | Page 5 of 36 |
|--------------------------------|--|--------------|

require bridging with enoxaparin because their onset of action is within 4 hours. (see later in policy).

3.3.4 Prophylaxis of deep vein thrombosis in surgical patients

The LMWH of choice for prophylaxis of DVT in surgical patients is Dalteparin (see table below for dosing and monitoring).

Or

Unfractionated heparin 5000 units subcutaneously 8 hourly

Owing to an increased risk of developing spinal haematoma, dalteparin **must not** be used for patients with an epidural catheter in situ, nor should it be administered within 12 hours to those patients who are to have an epidural catheter inserted. In these cases unfractionated heparin should be used, at a dose of 5000 units subcutaneously 8 hourly.

3.3.5 Prophylaxis of deep vein thrombosis in medical patients

The LMWH of choice for prophylaxis of DVT in medical patients is Dalteparin (see table below for dosing and monitoring).

3.3.6 Dalteparin dosing and monitoring for DVT prophylaxis

| Weight | Dalteparin dose | |
|-------------|-----------------------------------|------------------------------------|
| | Creatinine clearance ≥30ml/min | Creatinine clearance <30ml/min* |
| ≤ 49 kg | 2500 units once daily | 2500 units once daily* |
| 50 – 100 kg | 5000 units once daily | 5000 units once daily* |
| 101-149 kg | 5000 units twice daily* | 5000 units once daily* |
| ≥ 150 kg | 7500 units twice daily* | 5000 units once daily* |

*For patients >100kg or with a creatinine clearance is <30mls/min it is advisable to monitor anti-factor Xa levels. Blood samples should be taken before and 4 hours after the 3rd dalteparin dose has been given. If resultant levels are out of range, haematology should be consulted for dosing advice. Anti-Xa levels should be repeated once weekly to monitor for accumulation.

3.3.7 Further monitoring and communication for treatment doses of LMWH

Nursing staff administering LMWH must ensure they check the dose against the relevant dosing table prior to administering the drug

Prescribers should be vigilant of the need for continual review of the LMWH dose with respect to a patient's renal function

When a patient is transferred to another Trust or discharged on prolonged treatment (i.e. more than a few days), the patient's renal function and weight should be included in the transfer letter/TTO.

3.4 WARFARIN THERAPY (VITAMIN K ANTAGONIST THERAPY INCLUDING OTHER COUMARINS AND PHENINDIONE).

Warfarin is the most commonly used Vitamin K Antagonist (VKA) agent. Occasionally patients are intolerant of warfarin and may require treatment with other agents such as acenocoumarol (nicoumalone) or phenindione (or new oral anticoagulation agents –see Section 3.5). The dosing schedules for these agents differ from warfarin and haematological advice should be sought for acenocoumarol or phenindione. The principles of treatment are however the same as for warfarin.

Oral anticoagulants antagonise the effects of vitamin K. It takes 72 to 96 hours for the anticoagulant effect to develop. If an immediate effect is required, unfractionated or low molecular weight heparin must be given concomitantly. When changing from heparin to warfarin, heparin should be continued until therapeutic efficacy of warfarin has been confirmed by an INR greater than 2 on two consecutive days. Heparin should be discontinued if the measured INR exceeds the target range. The dose of warfarin should be titrated according to the measured INR (International Normalised Ratio).

Following cardiac surgery the target INR level and duration of warfarin therapy must be decided by the consultant responsible for the patient, due to the increased complexity of the LHCH case mix (if pacing wires are still in-situ a revised initial target may be required – see appendix one). Both the target level and range for the INR, together with the duration, should be entered within the EPR documentation and the target INR entered into the “anticoagulation reminder prescription” (within the anticoagulation order set) which will place this information into the EPR patient banner. If the patient was already taking warfarin, their pre-operation dose should be documented within EPR.

There are several clinical scenarios when patients may be prescribed warfarin which will be reviewed in the following sections:

- Starting warfarin in patients not previously anticoagulated (see section 3.4.1).
- Starting warfarin in patients already anticoagulated with heparin (see section 3.4.1).
- Restarting warfarin in patients whose anticoagulation has been interrupted for more than 3 days e.g. to allow for major cardiac surgery, (see section 3.4.2.1).
- Temporary discontinuation of warfarin to allow for cardiac procedures such as catheterization or pacemaker implantation, (see section 3.4.2.2).

3.4.1 Management of patients requiring initiation of oral anticoagulation therapy with warfarin.

Guidelines for the initiation of warfarin therapy are shown in Appendix 1. When starting anticoagulation therapy as an in-patient, patients must have their INR checked every day until their INR is stable. Prescribers must be aware that the dose administered is not reflected in the patient's INR for approximately three days. Lower doses than usual may be required in patients who are small (e.g. body weight less than 45kg), older patients, females and those with right sided heart pathology (e.g. after mitral valve surgery or with heart failure).

Patients being concurrently anticoagulated with heparin (either unfractionated or low molecular weight) should have warfarin therapy initiated in the same way as above, however, the heparin therapy should be discontinued once the INR is greater than 2.0, for two consecutive days. Heparin may be discontinued earlier if the patient is at higher than average risk of bleeding.

| | | |
|--------------------------------|--|--------------|
| Version No 7.0 October 2021 | Anticoagulation Current version is held on the Intranet Check with Intranet that this printed copy is the latest issue | Page 7 of 36 |
|--------------------------------|--|--------------|

3.4.1.1 Concomitant use of antiplatelet agents

For patients taking single antiplatelet agents in stable coronary artery disease, consideration should be made to stopping the antiplatelet whilst anticoagulated. For patients being treated with dual antiplatelet therapy and / or in the context of acute coronary syndrome, the decision on duration and dosage of triple therapy should be made by the senior doctor with respect to an individual; patient's bleeding risk versus embolic risk. Consideration should be made to stopping other drugs known to increase bleeding e.g. NSAIDs and to giving adequate gastro-protective agents.

3.4.2 Management of patients on oral anticoagulants requiring surgery or invasive procedures

Patients on oral anticoagulation should have the drug prescribed and suspended so that it is visible on EPR for review post procedure.

3.4.2.1 Surgical patients.

Warfarin is usually discontinued for five days prior to cardiac surgery and four days prior to thoracic surgery (see [Medicines during the peri-operative period policy](#)).

However, if surgery is delayed resulting in a gap of more than three days or if the patient has a mechanical valve then bridging anticoagulation with heparin should be discussed with the consultant in charge of the case. For dosing of heparin, see Appendix 3. Guidance on the management of patients on oral anticoagulation therapy requiring urgent surgery is shown in Appendix 7a.

3.4.2.2 Medical patients – temporary discontinuation of warfarin therapy for the peri- and intra- procedural management.

There are now extensive data that performance of device implants and EP procedures on continuous Warfarin is superior to the strategy of stopping warfarin and bridging with heparin for certain groups. Although occasionally management will need to be individually tailored, in general the approach will be to assign the patient into one of two risk groups as shown in Appendix 4.

N.B. For Electrophysiological procedures (EP) see separate Trust guidelines- “Guidelines for anticoagulation before, during and after EP procedures”

3.4.3 Prescribing of anticoagulation therapy

Prescribing within LHCH must comply with the Trust's Medicines Policy. The prescriber is legally responsible for their anticoagulation prescription and telephone orders should not be utilized. All anticoagulation therapy must be prescribed on the electronic prescribing system. For in-patients, the drug (for example, warfarin) together with the “anticoagulation therapy reminder prescription”, contained within the anticoagulation order set, must be prescribed at the same time.

3.4.4 Dosage and Administration

LHCH currently issues a combination of 1mg and 3mg Warfarin tablets (however, if a higher dose is required pharmacy, following discussion with the patient, may dispense 5mg tablets), each is labelled as follows:

| | | |
|--------------------------------|--|--------------|
| Version No 7.0 October 2021 | Anticoagulation Current version is held on the Intranet Check with Intranet that this printed copy is the latest issue | Page 8 of 36 |
|--------------------------------|--|--------------|

“Take daily at 6.00 p.m. as directed by the anticoagulation clinic”.

For in-patients, nursing staff will administer warfarin at 2pm. according to the Trust's administration procedure. Subcutaneous administration of heparin, intravenous heparin or low molecular weight heparin should be administered according to the Trust's administration procedure.

3.4.5 Communication with the anticoagulation clinic

Communication with the anticoagulation clinic taking over the patient's care is essential. Appendix Two shows the communication sheet (available on each ward printed in triplicate – top copy for the GP to be sent with the discharge summary, second copy for the anticoagulation clinic and third copy for the patient's case notes which can be scanned into EPR following discharge) to be used for onward communication with the patient's GP, anticoagulation clinic or hospital. An appointment must be made by telephone prior to the patient's discharge; however, the appointment must be confirmed by faxing the completed referral form.

This form should then be placed in the patient's purple folder and subsequently scanned into EPR.

All new patients (and any existing patients who need one) will receive an anticoagulation booklet at discharge containing details of their first anticoagulant outpatient appointment and details of the dose they will need to take initially. The details of the patient's first dose will be confirmed by pharmacy when dispensing the discharge prescription.

All new patients will be counselled on warfarin by either a pharmacist or a trained technician. A document to this effect will be completed within EPR.

3.4.6 Training of staff involved with anticoagulation therapy.

All staff involved with the prescribing, administration, dispensing and communication process for patients requiring anticoagulation therapy with warfarin will be trained to do so. This training will be appropriate to their role. Induction and mandatory training on medicines management within the Trust will be co-ordinated and managed by the training department, records of training will be held centrally within Human Resources. Specific training for doctors, nurses and pharmacists concerning their roles within this document and clinical aspects of anticoagulation therapy will be co-ordinated by the training pharmacist and clinical nurse trainers, this will be conducted at ward level or during specified training sessions. Records of this training will be held by the nurse trainers or the training pharmacist.

3.5 Non-Vitamin K Oral Anticoagulants (DOACS)

There are currently four DOAC agents, dabigatran, rivaroxaban, edoxaban and apixaban in use within the trust.

DOACs differ in many ways from warfarin, including rapid onset of action, shorter half-life, fewer drug-drug interactions, lack of need for monitoring and no need for titration or dose adjustments. In the absence of a specific clinical reason to select a particular DOAC, Edoxaban is the first line choice due to its simple dosing schedule (can be taken once daily and not affected by food) and lower acquisition cost.

| | | |
|--------------------------------|--|--------------|
| Version No 7.0 October 2021 | Anticoagulation Current version is held on the Intranet Check with Intranet that this printed copy is the latest issue | Page 9 of 36 |
|--------------------------------|--|--------------|

3.5.1 USE IN ATRIAL FIBRILLATION (ALSO SEE 3.5.3)

All four agents are licensed for stroke prevention in atrial fibrillation. There is also limited experience with their use for pulmonary vein isolation procedures and for cardioversion procedures.

Dabigatran, Rivaroxaban, Edoxaban and Apixaban have been approved by NICE for use for stroke prevention in the UK, DOACs have not been evaluated in patients with heart valve prostheses. Their safety and efficacy profiles in such patients cannot be determined and at present all such patients should remain on warfarin. Therefore, the trust will not initiate their use in patients with artificial valves.

Use of new agents in management of AF.

The focus of AF management should be to identify patients with AF and undertake a stroke risk assessment using the CHA₂DS₂VASc risk assessment tool (Appendix Five). Patients with a CHA₂DS₂VASc score greater than or equal to 1 should normally be considered for initiation of oral anti-coagulation therapy.

Assessing the bleeding risk, by using the HASBLED risk score, aids balancing the risk of stroke versus bleeding, shown in appendix six. However, unless there is a significantly larger bleeding risk, anticoagulation is generally indicated as the clinical outcome from a bleeding episode is preferable to a stroke. General caution is advised if HASBLED is greater than two.

Patients with previous intracranial bleed should be reviewed by a specialist stroke physician or neurologist.

Warfarin is traditionally the first line option for the prevention of stroke and systemic embolism in AF. Patients stable on warfarin therapy should not normally be considered for a switch to DOACs. DOACs should be considered as an alternative to warfarin for stroke prevention in AF in people with non-valvular atrial fibrillation with one or more of the following risk factors:

- Previous stroke, transient ischaemic attack or systemic embolism
- Left ventricular ejection fraction below 40%
- Symptomatic heart failure of New York Heart Association (NYHA) class 2 or above
- Age 75 years or older
- Age 65 years or older with one of the following: diabetes mellitus, coronary artery disease or hypertension

Priority patients for initiation of DOACs

These include:

- those currently taking warfarin with poor INR control, indicated by 2 or more unexplained INR values above 5.0 or below 1.7 during a twelve month period. Reasons for poor control should be explored (in particular poor compliance, interacting co-prescribed medication and diet) before treatment is changed.
- those with significant problems associated with the monitoring or taking of warfarin (either actual in those currently taking warfarin or likely in those considered appropriate for warfarin)

| | | |
|--------------------------------|--|---------------|
| Version No 7.0 October 2021 | Anticoagulation Current version is held on the Intranet Check with Intranet that this printed copy is the latest issue | Page 10 of 36 |
|--------------------------------|--|---------------|

- those who clearly express the desire not to take warfarin following an informed discussion of the risks and benefits of each agent.

DOACs are **not** a suitable alternative to warfarin in patients with bleeding complications associated with warfarin treatment, contraindications to warfarin therapy due to a high bleeding risk, poor compliance with warfarin therapy, a history of alcohol abuse or drug overdose or trivial side effects related to warfarin. Dabigatran is also contraindicated in moderate to severe renal impairment (creatinine clearance less than 30ml/min).

Aspirin (with or without clopidogrel) is not a suitable alternative to warfarin or DOACs in patients with atrial fibrillation and a CHA₂DS₂VASc score greater than or equal to 1, as it offers significantly less protection against stroke. Aspirin (with or without clopidogrel) should only be considered for such patients where warfarin and DOACs cannot be used due to allergy or contraindications.

Initiation of DOACs in AF.

DOACs should only be undertaken by clinicians with expertise in initiating anticoagulant therapy for stroke prevention in AF. The initiating clinician is responsible for the safe prescribing of DOACs including:

- Ensuring the patient meets the defined criteria for use
- Ensuring adequate follow up during the initiation phase including providing adherence counselling, dealing with side effects and addressing any patient concerns regarding therapy.

Initiation of DOACS in PVI patients See EP protocol

3.5.1.1 DABIGATRAN (SEE DATASHEET FOR FURTHER DETAILS)

- For the prevention of stroke and systemic embolism in atrial fibrillation, the standard dose is 150mg twice daily
- Patients aged 80 years or above should be treated with 110mg twice daily.
- Patients who receive dabigatran concomitantly with verapamil should have their dose reduced to 110mg twice daily.
- Patients with gastritis, oesophagitis, or gastro-oesophageal reflux, should also have their dose reduced to 110mg twice daily.
- Further advice is shown within Appendix 10.
- Please refer to the [Pan Mersey statement for the use DOACs in AF:](#)

3.5.1.2 RIVAROXABAN (SEE DATA SHEET FOR FURTHER DETAILS)

For prevention of stroke and systemic embolism in atrial fibrillation, the standard dose is 20 mg once daily. For patients with a creatinine clearance of 15 to 49 mL/min, the dose should be reduced to 15mg once daily. For patients with gastritis, oesophagitis or gastro-oesophageal reflux, gastro-protection may also be needed.

Further advice is shown within appendix 10.

Please refer to the [Pan Mersey statement for the use of DOACs in AF:](#)

| | | |
|--------------------------------|--|---------------|
| Version No 7.0 October 2021 | Anticoagulation Current version is held on the Intranet Check with Intranet that this printed copy is the latest issue | Page 11 of 36 |
|--------------------------------|--|---------------|

3.5.1.3 APIXABAN (SEE DATA SHEET FOR FURTHER DETAILS)

For prevention of stroke and systemic embolism in atrial fibrillation, the standard dose is 5 mg twice daily. A lower dose of 2.5 mg twice a day should be used for patients with at least two of the following characteristics: age greater than or equal to 80 years, body weight less than or equal to 60 kg, or serum creatinine greater than or equal to 133 micromol/L. For patients with a creatinine clearance of 15 to 29 mL/min the dose should also be reduced to of 2.5mg twice daily. For patients with gastritis, oesophagitis or gastro-oesophageal reflux, gastro-protection may also be needed.

Further advice is shown within appendix 10.

Please refer to the [Pan Mersey statement for the use of DOACs in AF](#):

3.5.1.4 EDOXABAN (SEE DATA SHEET FOR FURTHER DETAILS)

For prevention of stroke and systemic embolism in atrial fibrillation, the standard dose is 60 mg once daily. A lower dose of 30 mg once daily should be used for patients with at least with one or more of the following clinical factors:

Moderate or severe renal impairment (creatinine clearance (CrCL) 15 - 50 ml/min), low body weight ≤ 60 kg, concomitant use of the following P-glycoprotein (P-gp) inhibitors: ciclosporin, dronedarone, erythromycin, or ketoconazole. For patients with gastritis, oesophagitis or gastro-oesophageal reflux, gastro-protection may also be needed.

Further advice, is shown within appendix 10

Please refer to the Pan Mersey statement for the use in AF:

<http://www.panmerseyapc.nhs.uk/recommendations/documents/PS101.pdf?UNLID=4745308182015924105115>

3.5.2 USE IN TREATMENT AND PREVENTION OF DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM (PE) (ALSO SEE 3.5.3)

3.5.2.1 Dabigatran (SEE DATA SHEET FOR FURTHER DETAILS)

The recommended starting dose of dabigatran for the treatment or prevention of VTE in patients less than 80 years is 150mg twice daily. In patients 80 years or older or in those also taking verapamil, the dose should be reduced to 110mg twice daily.

Patients should receive at least 5 days treatment with a parenteral anticoagulant before starting dabigatran

Please refer to the [Pan Mersey statement for the use of DOACs in PE and DVT](#):

| | | |
|--------------------------------|--|---------------|
| Version No 7.0 October 2021 | Anticoagulation Current version is held on the Intranet Check with Intranet that this printed copy is the latest issue | Page 12 of 36 |
|--------------------------------|--|---------------|

3.5.2.2 Apixaban-(SEE DATA SHEET FOR FURTHER DETAILS)

The recommended starting dose of apixaban for the acute treatment of VTE is 10mg twice daily for 7 days followed by 5mg twice daily for 6 months. If treatment is to be continued beyond 6 months for the prevention of recurrent VTE, apixaban should be reduced to 2.5 mg twice daily.

Please refer to the [Pan Mersey statement for the use of DOACs in PE and DVT:](#)

3.5.2.3 Rivaroxaban (SEE DATA SHEET FOR FURTHER DETAILS),

The recommended starting dose of rivaroxaban is 15 mg twice daily for 21 days then either 20mg or 15mg daily depending on renal function.

Please refer to the [Pan Mersey statement for the use of DOACs in PE and DVT:](#)

3.5.2.4 Edoxaban (SEE DATA SHEET FOR FURTHER DETAILS)

The recommended dose is 60 mg edoxaban once daily following initial use of parenteral anticoagulant for at least 5 days. Edoxaban and initial parenteral anticoagulant should not be administered simultaneously.

Please refer to the [Pan Mersey statement for the use of DOACs in PE and DVT:](#)

3.5.3 OTHER CONSIDERATIONS IN DOAC USE

As the new agents are not subject to INR monitoring, there is no ready means to determine if a patient is concordant with their medication; prescribers should therefore also take into consideration whether the patient is likely/able to comply with their medication.

Concomitant use of antiplatelet agents

Studies with dabigatran, rivaroxaban, edoxaban and apixaban in patients with acute coronary syndromes, receiving combined antiplatelet therapy with aspirin and clopidogrel have generally shown a dose-dependent increase in the risk of major bleeding and any bleeding

For patients taking single antiplatelet agents in stable coronary artery disease, consideration should be made to stopping the antiplatelet whilst on anticoagulation.

For patients being treated with dual antiplatelets and/or in the context of acute coronary syndrome, the decision on duration and dosage of triple therapy should be made by the senior doctor with respect to an individual patients bleeding risk versus embolic risk. Consideration should be made to stopping other drugs known to increase bleeding e.g. NSAIDs and to giving adequate gastroprotective agents

3.5.4 Timing of interruption of DOACS before surgery or invasive procedures.

Patients on oral anticoagulation should have the drug prescribed and suspended so that it is visible on EPR for review post procedure

For medical patients see Appendix 4 (see separate policy for EP procedures)

| | | |
|--------------------------------|--|---------------|
| Version No 7.0 October 2021 | Anticoagulation Current version is held on the Intranet Check with Intranet that this printed copy is the latest issue | Page 13 of 36 |
|--------------------------------|--|---------------|

Procedures with a standard risk of bleeding, where an INR of 1.5 for patients on warfarin would be acceptable include cardiac catheterisation, diagnostic endoscopy, minor orthopaedic surgery. .

Advice for device procedures has been updated taking account of current EHRA and ACC guidance – see Appendix 4 ^{2,3}

For surgical patients see Appendix 10 and [Medicines during the peri-operative period policy](#)

The table in Appendix 10 summarises discontinuation advice before invasive or surgical procedures.

Any surgery/intervention should be delayed if possible until at least 12 hours after the last dose. If surgery cannot be delayed, there may be an increase in the risk of bleeding. This risk of bleeding should be weighed against the urgency of intervention.

3.5.5 Postoperative management

For medical patients refer to Appendix 4

For surgical patients consult senior members of team

Note that DOACs have a rapid onset of action.

Advice for device procedures has been updated taking account of current EHRA and ACC guidance. If normal haemostasis is achieved and the operator has no concerns, DOACs can usually be restarted the day after (12-24 hours) post procedure. ^{2,3}

3.6 ANTICOAGULATION PROBLEMS OR COMPLICATIONS

3.6.1 Heparin Immune (Induced) Thrombotic Thrombocytopenia (HITT).

See HITT Policy.

3.6.2 Management of haemorrhage

3.6.2.1 Warfarin

- Inform Consultant
- Major bleed – stop warfarin, give phytomenadione (vitamin K₁) 5 mg by slow intravenous injection, or prothrombin complex concentrate (factors II, VII, IX and X) 50 units/kg
- INR greater than 8, no bleeding or minor bleeding – stop warfarin, restart when INR less than 5, if there are other risk factors for bleeding give phytomenadione (vitamin K₁) 0.5mg by slow intravenous injection or 5mg by mouth, for partial reversal of anticoagulation give smaller oral doses of phytomenadione e.g. 0.5 to 2.5 mg (using the paediatric intravenous preparation orally), repeat dose of phytomenadione if INR still too high after 24 hours.
- INR 6 – 8, no bleeding or minor bleeding – stop warfarin, restart when INR less than 5.

| | | |
|--------------------------------|--|---------------|
| Version No 7.0 October 2021 | Anticoagulation Current version is held on the Intranet Check with Intranet that this printed copy is the latest issue | Page 14 of 36 |
|--------------------------------|--|---------------|

- INR 5 - 6 , reduce dose or stop warfarin, restart when INR less than 5
- Unexpected bleeding at therapeutic levels – always investigate possibility of underlying cause e.g. unsuspected renal or gastrointestinal tract pathology.

3.6.2.2 DOACs

Emergency testing of haemostatic function for DOACs

Dabigatran

If the thrombin clotting time TCT is normal, the level of dabigatran is very low. (PT) is insensitive to dabigatran and not useful. Point of care testing INR values may be inaccurate in patients receiving dabigatran and should not be used to judge drug effect. At high dabigatran concentrations the aPTT becomes incoagulable but interpretation of the results is difficult and haematology advice should be sought. A normal aPTT would suggest that haemostatic function is not impaired.

Rivaroxaban and Apixaban

The PT is prolonged but the PT response to both drugs is assay dependant and haematology advice should be sought. A normal PT would suggest that haemostatic function is not impaired.

Managing overdose- see appendices 7b, 7c and 9

Dabigatran

If detected soon after ingestion the absorption of dabigatran may be reduced by gastric lavage and/or administration of charcoal. Prothrombin complex concentrate (PCC, Octaplex) may improve haemostasis by providing small amounts of thrombin. Haemodialysis may be useful since only 35% of dabigatran is bound to plasma proteins. In emergency situations – for example a patient on Dabigatran requiring emergency surgery – the antidote for dabigatran – idarucizumab – may be used.

Rivaroxaban

Due to a high degree of albumin binding in plasma (92-95%), rivaroxaban dialysis would not be useful. Prothrombin complex concentrate (PCC, Octaplex) should be administered in a dose of 50 IU/kg in case of life-threatening bleeding.

Apixaban

Administration of activated charcoal may be useful in the management of apixaban overdose or accidental ingestion.

If life-threatening bleeding cannot be controlled by conservative measures, administration of recombinant factor VIIa may be considered. Re-dosing of recombinant factor VIIa could be considered and titrated depending on improvement of bleeding.

Edoxaban

For life-threatening bleeding that cannot be controlled with the measures such as transfusion or haemostasis, the administration of a 4-factor prothrombin complex concentrate (PCC) at 50 IU/kg has been shown to reverse the effects of edoxaban 30 minutes after completing the infusion.

| | | |
|--------------------------------|--|---------------|
| Version No 7.0 October 2021 | Anticoagulation Current version is held on the Intranet Check with Intranet that this printed copy is the latest issue | Page 15 of 36 |
|--------------------------------|--|---------------|

Recombinant factor VIIa (r-FVIIa) can also be considered. However, there is limited clinical experience with the use of this product in individuals receiving edoxaban.

Managing bleeding complications

When bleeding occurs the event should be risk stratified: Minor bleeding (such as epistaxis, ecchymosis, or menorrhagia) should be managed with simple withdrawal of the anticoagulant for one or more days allowing definitive interventions to be applied. The drug could then be restarted. Moderate bleeding (such as upper or lower gastrointestinal bleeding) should be managed with withdrawal of the anticoagulant, careful clinical monitoring, interventions to identify and definitively treat the bleeding source and consideration of an extended period of withdrawal of the oral anticoagulant to allow healing.

Major and life-threatening bleeding should be treated as follows:

For Dabigatran the antidote idarucizimab should be administered at a dose of 5g. A second dose may be given if there is recurrence of severe bleeding with a prolongation of the clotting time or a second surgery is required. For all other DOACs treatment is supportive with resuscitation measures, immediate anticoagulant withdrawal, aggressive clinical monitoring, transfusion of packed red blood cells and interventions to identify and treat the bleeding source (requiring endoscopy, interventional radiology or surgery). Prothrombin complex concentrate (PCC, Octaplex) may improve haemostasis by providing small amounts of thrombin. Prothrombin complex concentrate (PCC) should be administered in a dose of 50 IU/kg in case of life-threatening bleeding. Haemodialysis may be useful for dabigatran but not for rivaroxaban or apixaban, and should be used if bleeding continues despite administration of idarucizimab.

Dabigatran treatment can be re-initiated 24 hours after administration of Praxbind, if the patient is clinically stable and adequate haemostasis has been achieved.

4. Policy Implementation Plan

This policy will be disseminated via the Drug and Therapeutics Committee. All ward managers received an information pack via their ward pharmacist during implementation of the first version of this policy, however, further training sessions will be arranged at ward level by ward pharmacists to ensure nurses are aware of this policy. The policy will be explained to all medical staff during their induction training and during their medicines management training sessions.

The policy will become part of a check list for all clinical staff to read during induction, records of this training will be held within the Human Resources Department.

Managers have a responsibility to ensure staff have read and understood the policy and a record of this should be kept. Pharmacy will carry out an annual audit of anticoagulation practice within the Trust which will be reported to Drug and Therapeutics Committee. Audit results demonstrating (lack of) adherence may require the author to develop local strategies for further dissemination. The policy will be updated following feedback from audit results.

With the introduction of the first version of this policy the new anticoagulation booklet was introduced to the Trust following recommendation by the National Patient Safety Agency. A new communication sheet was also introduced for use by the wards for the onward dissemination of

| | | |
|--------------------------------|--|---------------|
| Version No 7.0 October 2021 | Anticoagulation Current version is held on the Intranet Check with Intranet that this printed copy is the latest issue | Page 16 of 36 |
|--------------------------------|--|---------------|

anticoagulation information to referring hospitals, anticoagulation clinics and GP surgeries. The booklet and communication sheet will continue to be used.

5. Monitoring of Compliance

Audit of the policy will be conducted annually by the audit department via incident reports and via audit of the communication sheet to ensure onward communication of patient's anticoagulation therapy has been undertaken. Pharmacy will conduct an annual audit of clinical issues in line with NPSA guidance.

6. Expert Advice

Advice on the development of this policy has been obtained from the haematology department at the RLBUHT and Wirral NHS Trust.

7. References

1. Fennerty et al. British Medical Journal 1988;297:1285-8
2. Jan Steffel, Peter Verhamme, Tatjana S Potpara, Pierre Albaladejo, Matthias Antz, Lien Desteghe, Karl Georg Haeusler, Jonas Oldgren, Holger Reinecke, Vanessa Roldan-Schilling, Nigel Rowell, Peter Sinnaeve, Ronan Collins, A John Camm, Hein Heidbüchel, The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation, European Heart Journal, Volume 39, Issue 16, 21 April 2018, Pages 1330–1393, <https://doi.org/10.1093/eurheartj/ehy136>
3. Doherty JU., Gluckman TJ., Hucker WJ., Januzzi JL., , Ortel TL., Saxonhouse SJ., Spinler SA. (2017) ACC Expert Consensus Decision Pathway for Periprocedural Management of Anticoagulation in Patients with Nonvalvular Atrial Fibrillation: A Report of the American College of Cardiology Clinical Expert Consensus Document Task Force, Journal of the American College of Cardiology Volume 69, Issue 7, 2017, Pages 871-898.

| | | |
|--------------------------------|--|---------------|
| Version No 7.0 October 2021 | Anticoagulation Current version is held on the Intranet Check with Intranet that this printed copy is the latest issue | Page 17 of 36 |
|--------------------------------|--|---------------|

8. Appendices

APPENDIX 1

WARFARIN INITIATION SCHEDULE

The information contained in this appendix is divided into three sections:

A, Post Cardiac surgery dosing,

B, Dosing for the prevention of complications for atrial fibrillation patients (in the out-patient setting)

C, Warfarin initiation schedule for guidance in all other in-patients.

A. Post Cardiac surgery:

Schedules for oral anticoagulant therapy after cardiac surgery are different to all other LHCH in-patients .

An initial dose of 0.5 to 1mg/10Kg body weight is given unless any of the following conditions apply:

Day one post-operative INR greater than 1.4

Weight less than 55Kg or more than 100Kg

Abnormal liver function

Right heart failure

Antibiotic therapy or other concomitant drug(s) that may interact with warfarin (if in doubt contact pharmacy for information).

The dose schedule of warfarin should be discussed with the registrar or consultant of the team involved should any of the above criteria exist. The above regimen should be used in all in-patients to achieve the desired target INR. It may be necessary to aim initially for an INR of 2.0 to 2.5 in patients where pacing wires are still in-situ. Once the pacing wires have been removed the interim INR can be crossed through on the prescription chart and the desired INR (as determined by the consultant) can be prescribed.

Subsequently daily warfarin doses should be determined by review of the patient's INR and by discussion with the consultant in charge of the case.

B. Prevention of complications for atrial fibrillation patients (in the out-patient setting).

Warfarin may be commenced in the out-patient setting. Patients may be commenced using a dose that is deemed to be an appropriate maintenance dose for that patient, however, it is important to ensure that all patients commenced in this manner have access to an anticoagulation clinic 72 hours after starting their anticoagulation.

| | | |
|--------------------------------|--|---------------|
| Version No 7.0 October 2021 | Anticoagulation Current version is held on the Intranet Check with Intranet that this printed copy is the latest issue | Page 18 of 36 |
|--------------------------------|--|---------------|

C. All other LHCH in-patients

The following table refers to initiation of warfarin therapy ONLY and SHOULD NOT be used as a guide to maintenance dose adjustment.

| Day | INR | Warfarin dose (mg) |
|-----------|----------------------------------|--|
| Day 1 (*) | Less than 1.4 (Before treatment) | 10 (1 st dose) |
| Day 2 | Less than 1.8 | 10 |
| | 1.8 | 1 |
| | Greater than 1.8 | 0.5 |
| Day 3 | Less than 2 | 10 |
| | 2 – 2.1 | 5 |
| | 2.2 – 2.3 | 4.5 |
| | 2.4 – 2.5 | 4 |
| | 2.6 – 2.7 | 3.5 |
| | 2.8 – 2.9 | 3 |
| | 3 – 3.1 | 2.5 |
| | 3.2 – 3.3 | 2 |
| | 3.4 | 1.5 |
| | 3.5 | 1 |
| | 3.6 – 4 | 0.5 |
| | 4 | 0 |
| | | Predicted maintenance dose |
| Day 4 | Less than 1.4 | More than 8 |
| | 1.4 | 8 |
| | 1.5 | 7.5 |
| | 1.6 – 1.7 | 7 |
| | 1.8 | 6.5 |
| | 1.9 | 6 |
| | 2 – 2.1 | 5.5 |
| | 2.2 – 2.3 | 5 |
| | 2.4 – 2.6 | 4.5 |
| | 2.7 – 3 | 4 |
| | 3.1 – 3.5 | 3.5 |
| | 3.6 – 4 | 3 |
| | 4.1 – 4.5 | Miss out next day's dose then give 2mg |
| | Greater than 4.5 | Miss out 2 day's doses then give 1mg |

* Day 1 INR greater than 1.4 – seek specialist haematology advice
Other induction regimens to be used at the discretion of the Consultant.

APPENDIX 2

Communication Sheet - Request for Outpatient Anticoagulant Control

****For Arrowe Park Hospital see separate form below****

| Surname | Forename | Unit Number | Date of Birth | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|---|--|---|---|---------------------------|---------|------------------|------------|----------------------|----------------|--|--|---------------------|-----------------------|--------------|--------------|-------------------------|-------------------|--------------|--------------|--------------|------------|--------------|--------------|-------------------------|--------------------|---------------|---------------|-----------------|---------------|---------------|---------------|
| Patients Address | | General Practitioner Name | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Postal code | | GP Address | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Phone No. | | GP Phone No. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Ward / Clinic | Consultant | Date of next Consultant appt. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Indication for Anticoagulation | Relevant Previous Medical History | INR Target Recommended ((with range) | Duration of Treatment | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Date Warfarin Started (if not warfarin, indicate drug) | INR on Discharge | Appointment Date for INR Check | Antiplatelet therapy required YES NO | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Hospital INR History | | Other Drugs Prescribed | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Date | INR | Dose | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Anticoagulation clinic to be referred to: <table border="1"> <thead> <tr> <th>Name of clinic / hospital</th> <th>Address</th> <th>Telephone Number</th> <th>Fax Number</th> </tr> </thead> <tbody> <tr> <td>Arrowe Park Hospital</td> <td>See form below</td> <td></td> <td></td> </tr> <tr> <td>Countess of Chester</td> <td>Liverpool Rd, Chester</td> <td>01244 365373</td> <td>01244 365122</td> </tr> <tr> <td>Halton General Hospital</td> <td>Runcorn, Cheshire</td> <td>01928 753213</td> <td>01928 753922</td> </tr> <tr> <td>Ormskirk DGH</td> <td>Wigan Road</td> <td>01695 656890</td> <td>01695 656819</td> </tr> <tr> <td>Road Dahl Centre RLBUHT</td> <td>Prescott Street L1</td> <td>0151 706 3393</td> <td>0151 706 5837</td> </tr> <tr> <td>Walton Hospital</td> <td>Rice Lane, L9</td> <td>0151 529 4421</td> <td>0151 529 4626</td> </tr> </tbody> </table> | | | | Name of clinic / hospital | Address | Telephone Number | Fax Number | Arrowe Park Hospital | See form below | | | Countess of Chester | Liverpool Rd, Chester | 01244 365373 | 01244 365122 | Halton General Hospital | Runcorn, Cheshire | 01928 753213 | 01928 753922 | Ormskirk DGH | Wigan Road | 01695 656890 | 01695 656819 | Road Dahl Centre RLBUHT | Prescott Street L1 | 0151 706 3393 | 0151 706 5837 | Walton Hospital | Rice Lane, L9 | 0151 529 4421 | 0151 529 4626 |
| Name of clinic / hospital | Address | Telephone Number | Fax Number | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Arrowe Park Hospital | See form below | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Countess of Chester | Liverpool Rd, Chester | 01244 365373 | 01244 365122 | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Halton General Hospital | Runcorn, Cheshire | 01928 753213 | 01928 753922 | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Ormskirk DGH | Wigan Road | 01695 656890 | 01695 656819 | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Road Dahl Centre RLBUHT | Prescott Street L1 | 0151 706 3393 | 0151 706 5837 | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Walton Hospital | Rice Lane, L9 | 0151 529 4421 | 0151 529 4626 | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Signature of Doctor | | Date | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

ANTICOAGULANT OUTPATIENTS CLINIC REFERRAL FORM

Please note that appointments will only be made when all sections are fully completed

| | | | | |
|--|----------------|------------------------------|--------------|----------------|
| REFERRER DETAILS | Referring Unit | Name of Referring Consultant | Contact Name | Contact Tel N° |
| | | | | Contact Fax N° |
| If discharged from acute care please state location: | | | Ward: | Discharge Date |

| | | | |
|------------------------|----------|----------|---------------|
| PATIENT DETAILS | Surname | Forename | Date Of Birth |
| | Address | | Telephone N° |
| | | | MRN |
| | Postcode | | NHS number |

| | | | |
|-------------------|---------|------------|-------------|
| GP DETAILS | GP Name | GP Address | GP Phone N° |
|-------------------|---------|------------|-------------|

ANTICOAGULATION INFORMATION

| Indication (Please circle) | | | Target INR (Please circle) | INR Range (Please circle) | Duration of treatment (Please circle) |
|-------------------------------|-----------|-----------|-------------------------------|------------------------------|--|
| DVT | PE | AF | 2.5 | 2 to 3 | 3 months 6 months Long term |
| Other (please state) | | | 3.5 | 3 to 4 | Other (Please state) |
| | | | Other (please state) | Other (please state) | |

To help with patient counselling : If the indication for anticoagulation is atrial fibrillation please state CHA₂DS₂VASc or CHADS₂ score

CHA₂DS₂VASc

CHADS₂

If patient is to have DC cardioversion please state date of appointment :

Has the patient been newly commenced on oral anticoagulant therapy?
(Please circle) Yes or No

Name of anticoagulant

Please state date anticoagulant started if applicable:

Is the patient currently prescribed an antiplatelet?
(Please circle) Yes or No

Name of antiplatelet (please circle)

Aspirin Dipyridamole
Clopidogrel Other:

Is the antiplatelet to stop when INR reaches therapeutic level?
(Please circle)

Yes or No

| | | | | |
|-----------------------------|------|------------|----------------------|---|
| PREVIOUS INR RESULTS | Date | INR result | Anticoagulant Dose : | <p>TO BOOK APPOINTMENT TELEPHONE 0151 604 7393</p> <p>CONFIRM REQUEST BY FAXING REFERRAL TO 0151 604 0370</p> |
| | | | | |
| | | | | |
| | | | | |

SIGNATURE OF REFERRING CLINICIAN

DATE OF REFERRAL

For anticoagulant clinic clerk use only:

| | | | |
|-----|-------------------------|---------------|--------------------|
| MRN | Clinic Appointment date | Date actioned | Actioned by (name) |
| | | | |

Form produced by Alice Foster WUTH Specialist Anticoagulant Pharmacist
Approved: WHAG October 2012 Review Date: October 2015

APPENDIX 3

| | | |
|--------------------------------|--|---------------|
| Version No 7.0 October 2021 | Anticoagulation Current version is held on the Intranet Check with Intranet that this printed copy is the latest issue | Page 21 of 36 |
|--------------------------------|--|---------------|

Heparin Infusion Guidelines

How to Use Intravenous Heparin in Adults*

1. Give a bolus – loading dose of 5,000 units by intravenous injection (see below). Patients less than 70Kg should receive approximately 70 units/Kg as a loading dose.
2. Establish an infusion of heparin 1000units/ml (40ml containing 40,000units). Set infusion to run at 1.3ml per hour (approximately 30,000 units over 24 hours).
3. Check APTT 6 to 8 hours after starting infusion.
4. Change the infusion rate to achieve the therapeutic APTT ratio range of 1.8 to 3.3 (depending on indication and concurrent therapy) by 24 hours (see table).

| <i>For Adjusting the Dosage of Intravenous Heparin 1000 units/ml</i> | |
|---|--|
| APTT Ratio | Infusion rate change |
| Greater than 7.2 | Stop for 60 minutes. At restart, reduce rate by 1ml/hr. |
| 5.7 – 7.1 | Reduce by 0.3ml/hr. |
| 3.4 – 5.6 | Reduce by 0.1ml/hr. |
| 1.8 – 3.3 | No change. |
| 1.4 – 1.7 | Increase by 0.2ml/hr. |
| Less than 1.4 | Increase by 0.4ml/hr. |
| Repeat APTT ratio 6-8hours after each alteration in rate, unless APTT ratio is greater than 7.2 when measurements should be made more frequently. | |

*Modified from Fennerty et al. British Medical Journal 1988;297: 1285-8

5. Replace heparin infusion (syringe) at least every 24 hours and repeat APTT daily, or more frequently if infusion rate is altered (as above).
6. If heparin continues for more than 5 days, check platelet count and serum potassium level daily.

For patients less than 50kg or patients known to be sensitive to heparin, discuss with the consultant or hematology department.

APPENDIX 4

PROTOCOL FOR THE PERI-PROCEDURAL MANAGEMENT OF MEDICAL PATIENTS RECEIVING REGULAR ORAL ANTICOAGULANTS

THE FOLLOWING TABLE APPLIES TO PATIENTS ON WARFARIN, ACENOUMAROL AND PHENINDIONE:

| Stratify patients according to risk for thrombo-embolism | |
|---|--|
| High risk (1 or more of the following) <ul style="list-style-type: none"> • Mechanical mitral valve • Tilting disc/Caged –ball heart valve • AF:CHADS score >4 • Recent thromboembolism within 3 months | Low-Medium risk <ul style="list-style-type: none"> • Bi-leaflet aortic valve • AF: CHADS score ≤4 • Remote thrombo embolism |
| Pre-procedural management (NB for non-radial access-discuss with consultant) | |
| Continue warfarin without dose reduction AIM FOR INR<3.0 | Stop warfarin for 4 days and aim for INR <2.5 |
| Post-procedural management | |
| <ul style="list-style-type: none"> • Continue warfarin post wound check • No low molecular weight heparin unless explicitly requested | <ul style="list-style-type: none"> • Resume usual dose warfarin on same day post wound check • No low molecular weight heparin unless explicitly requested |

THE FOLLOWING TABLE APPLIES TO PATIENTS ON DOACs

Dabigatran

| Preoperative management; Timing of last dose prior to procedure | | |
|---|-----------------------------|--------------------------|
| Estimated Creatinine Clearance (ml/min) | Standard risk of bleeding** | High Risk of Bleeding*** |
| >50 | 24 hours | 2 days |
| 30-50 | 2 days | 4 days |
| <30* | 4 days | 6 days |
| Postoperative management: Re-initiation post-procedure | | |
| | Standard risk of bleeding** | High Risk of Bleeding*** |
| | 24 hours | 48 hours |

Rivaroxaban/Apixaban/Edoxaban

| Preoperative management; Timing of last dose prior to procedure | | |
|---|--|--|
| Estimated Creatinine Clearance (ml/min) | Standard risk of bleeding** | High Risk of Bleeding*** |
| >30 | 24 hours | 2 days |
| 15-30 | 2 days | 4 days |
| Postoperative management: Re-initiation post-procedure | | |
| | Standard risk of bleeding** | High Risk of Bleeding*** |
| | Consider at least 12hours post procedure after wound check | Consider at least 12hours post procedure after wound check |

***Note dabigatran treatment is contraindicated in these patients**

For all EP and ablation procedures, including PVI refer to Trust policy for anticoagulation during EP procedures

| | | |
|--------------------------------|--|---------------|
| Version No 7.0 October 2021 | Anticoagulation Current version is held on the Intranet Check with Intranet that this printed copy is the latest issue | Page 23 of 36 |
|--------------------------------|--|---------------|

Device Procedures

**** Standard risk includes the following device procedures: New pacemaker/ICD/CRT implant (including leadless pacemakers and subcutaneous ICDs), generator changes**

***** High risk includes the following device procedures: Device upgrades, lead extraction, wound revision, submuscular reburial**

DOACs can usually be restarted 12-24 hours post procedure if the wound is satisfactory but individualised advice will be documented in the Cardiac Devices post procedure review document

| | | |
|--------------------------------|--|---------------|
| Version No 7.0 October 2021 | Anticoagulation Current version is held on the Intranet Check with Intranet that this printed copy is the latest issue | Page 24 of 36 |
|--------------------------------|--|---------------|

APPENDIX 5

CHA₂DS₂VASc Score

The risk factor-based approach for patients with non-valvular AF can be expressed as an acronym, CHA₂DS₂VASc [congestive heart failure, hypertension, age ≥75 (doubled), diabetes, stroke (doubled), vascular disease, age 65–74, and sex category (female)]. This scheme is based on a point system in which 2 points are assigned for a history of stroke or TIA, or age ≥75; and 1 point each is assigned for age 65–74 years, a history of hypertension, diabetes, recent cardiac failure, vascular disease (myocardial infarction, complex aortic plaque, and PAD, including prior revascularization, amputation due to PAD, or angiographic evidence of PAD, etc.), and female sex.

CHA₂DS₂VASc score and stroke rate

Risk factor-based approach expressed as a point based scoring system, with the acronym CHA₂DS₂VASc

(Note: maximum score is 9 since age may contribute 0, 1, or 2 points)

| | |
|--|----------|
| Congestive heart failure/LV dysfunction | 1 |
| Hypertension | 1 |
| Age >75 | 2 |
| Diabetes mellitus | 1 |
| Stroke/TIA/thrombo-embolism | 2 |
| Vascular disease | 1 |
| Age 65–74 | 1 |
| Sex category (i.e. female sex) | 1 |

Maximum score 9

Adjusted stroke rate according to CHA₂DS₂-VASc score

Based on data from 7329 patients. Lip GY, Frison L, Halperin JL, Lane DA. Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke 2010;41 (12):2731–8. 0

| | |
|----------|--------------|
| 0 | 0% |
| 1 | 1.3% |
| 2 | 2.2% |
| 3 | 3.2% |
| 4 | 4.0% |
| 5 | 6.7% |
| 6 | 9.8% |
| 7 | 9.6% |
| 8 | 6.7% |
| 9 | 15.2% |

Bleeding Risk Assessment Tools

Anticoagulant risk / benefit assessment

Risk benefit assessment involves making a clinical assessment in respect of the safety or otherwise of commencing or continuing anticoagulation. Relevant indicators to look out for include:

- Major spontaneous bleeding complications including gastrointestinal, intracranial bleeding etc.
- Deterioration in cognitive function , onset of dementia etc. (e.g. patient unable to remember whether has taken medication or not)
- Recurrent accidental falls with head injury or likely to lead to head injury
- Requirement for new medication likely to potentiate risk of bleeding e.g. aspirin or Clopidogrel
- Significant deterioration in renal or hepatic function (both likely to increase bleeding risk)

Warfarin: Stability of anticoagulation (widely fluctuating INRs with no obvious cause may indicate a higher risk of bleeding, stable INR control is associated with a more favourable bleeding risk profile)

| HAS-BLED Major Bleeding Risk Score | Clinical Characteristic | Points | HAS-BLED score total points |
|------------------------------------|---------------------------------|--------|-----------------------------|
| H | Hypertension | 1 | 0 |
| A | Abnormal renal & liver function | 1 or 2 | 1 |
| S | Stroke | 1 | 2 |
| B | Bleeding diatheses | 1 | 3 |
| L | Labile INR | 1 | 4 |
| E | Elderly | 1 | 5 to 9 |
| D | Drugs/ Alcohol | 1 or 2 | |

Pisters R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093–1100.

APPENDIX 7(a)

COUMARINS (E.G. WARFARIN) MANAGEMENT OF ANTICOAGULATED PATIENTS REQUIRING URGENT SURGERY

Step 1

- Send sample for INR
- Give Vitamin K IV 2.0 mg (slow injection or infusion in Glucose 5%) to all patients, if INR > 2.5
- Stop warfarin

Step 2a (Surgery within 6 hours required)

- Give prothrombin complex concentrate (PCC) 30 units per kg IV in addition to Vitamin K
- PCC will reverse warfarin / normalize INR within 10 – 15 minutes
- PCC (Octaplex) is available from the Transfusion Laboratory (see appendix 8)
- Round dose to use full vials (500 units per vial)
- Send sample for INR post-PCC
- If necessary proceed with surgery immediately post PCC (without waiting for INR result)

Step 2 b (Surgery can be delayed > 6 hours)

- Check INR 6 hours post Vitamin K. Proceed if INR < 1.6.
INR between 1.5 and 2.0 may be safe for some procedures.
- If INR still deranged despite Vitamin K give another 2.0 mg of Vitamin K IV and consider PCC (see above)

Step 3 (Bridging anticoagulation)

- Patients with a moderate/high risk of thromboembolism (see below) need bridging anticoagulation
- If bridging anticoagulation is indicated, refer to Appendix 4 high risk patients and section 3.4.2.1
- If surgery is delayed start bridging anticoagulation pre-op (either unfractionated heparin or low molecular weight heparin, discuss with consultant in charge of the case. Start when INR < 2.0. Give last dose of enoxaparin 12 hours before the operation (e.g. 18.00 the day before)
- Start bridging anticoagulation 12 – 24 h after the operation when considered safe with respect to surgical bleeding.

Step 4 (Post-operative management)

- Check INR and FBC next morning
- Restart warfarin as soon as the patient is eating and drinking normally
- Continue enoxaparin 1.0mg/kg twice daily as above or unfractionated heparin on the 2nd or 3rd postoperative day when the risk of bleeding is considered lower
- Stop bridging anticoagulation with enoxaparin or unfractionated heparin when INR in therapeutic range
- Bridging anticoagulation and re-introduction of warfarin can be completed in the community following discharge

For all steps seek advice from haematology

Comments

- The “watch and wait” - approach (stop warfarin and wait until INR comes down) is too slow, results in significant delays and prolongs length of stay. This practice should be abandoned.
- All patients should be given Vitamin K. Oral Vitamin K has a very slow onset and the effect is unreliable. Intravenous Vitamin K should be used instead.
- The dose of intravenous Vitamin K suggested here (2.0mg) represents a compromise. Lower doses may be insufficient to reverse warfarin, higher doses may make re-anticoagulation difficult.
- FFP should not be used for reversal of warfarin because a) the reversal may be incomplete b) it is slow c) there is a risk of infection and transfusion-related acute lung injury d) it can result in fluid overload.
- The clotting factors (prothrombin complex concentrate) given to reverse warfarin have a short half-life of only 4 – 6 hours (Factor VII). Therefore, surgery should be performed as early as possible after the administration of clotting factors.
- It is essential that intravenous (IV) vitamin K is given in addition to PCC to switch on endogenous synthesis of vitamin K dependent clotting factors.
- Warfarin has a slow onset of action. Therefore, it can safely be restarted at the regular dose on the evening after the operation provided the patient can have oral medication and is resuming a normal diet (if patient still has post-procedural drains in situ, consult with consultant).

APPENDIX 7(b)
DABIGATRAN


Toolkit for the Management of Massive Haemorrhage

Algorithm for management of bleeding (and urgent reversal in case of need for emergency surgery) in patients on dabigatran

Dabigatran is a direct thrombin inhibitor with a half life of 14-17 hours.

Dabigatran is renally excreted and the half life is prolonged in renal impairment.

There is a licensed reversal agent for Dabigatran which should be administered in the case of life threatening bleeding..



¹**Moderate to Severe bleeding:** - reduction in Hb ≥ 2gd/L, transfusion of ≥ 2 units of red cells or symptomatic bleeding in critical area (i.e. intraocular, intracranial, intraspinal, intramuscular with compartment syndrome, retroperitoneal, intraarticular or pericardial bleeding).


²**Life-threatening bleeding:** – symptomatic intracranial bleed, reduction in Hb ≥ 5gd/L, transfusion of ≥ 4 units of red cells, hypotension requiring inotropic agents or bleeding requiring surgical intervention.

Toolkit for the Management of Massive Haemorrhage

Algorithm for management of bleeding (and urgent reversal in case of need for emergency surgery) in patients on rivaroxaban / apixaban/edoxaban

Rivaroxaban, Edoxaban and Apixaban are factor Xa inhibitors. Rivaroxaban, Edoxaban and Apixaban have half lives of 7-11 hours, 10-14 hours and 12 hours respectively

There is no licensed reversal agent for these drugs.



¹**Moderate to Severe bleeding:** - reduction in Hb \geq 2gd/L, transfusion of \geq 2 units of red cells or symptomatic bleeding in critical area (i.e. intraocular, intracranial, intraspinal, intramuscular with compartment syndrome, retroperitoneal, intraarticular or pericardial bleeding).

²**Life-threatening bleeding:** – symptomatic intracranial bleed, reduction in Hb \geq 5gd/L, transfusion of \geq 4 units of red cells, hypotension requiring inotropic agents or bleeding requiring surgical intervention.

APPENDIX 8

Enoxaparin 1.5mg/kg once daily (e.g. PVI, DVT and PE Treatment) - USE ONLY 120mg or 150mg syringes- Each Graduation is 3mg

| Weight (Kg) | Syringe Dose (mg) | NB Dose for patients with Creatinine Clearance less than 30ml/minute is 1mg/kg once daily | |
|-------------|-----------------------------------|---|-------------------|
| | | Weight (kg) | Syringe dose (mg) |
| 50 | 75 | 50-52 | 51 |
| 51-52 | 78 | 53-55 | 54 |
| 53-54 | 81 | 56-58 | 57 |
| 55-56 | 84 | 59-61 | 60 |
| 57-58 | 87 | 62-64 | 63 |
| 59-60 | 90 | 65-67 | 66 |
| 61-62 | 93 | 68-70 | 69 |
| 63-64 | 96 | 71-73 | 72 |
| 65-66 | 99 | 74-76 | 75 |
| 67-68 | 102 | 77-79 | 78 |
| 69-70 | 105 | 80-82 | 81 |
| 71-72 | 108 | 83-85 | 84 |
| 73-74 | 111 | 86-88 | 87 |
| 75-76 | 114 | 89-91 | 90 |
| 77-78 | 117 | 92-94 | 93 |
| 79-80 | 120 | 95-97 | 96 |
| 81-82 | 123 | 98-100 | 99 |
| 83-84 | 126 | 101-103 | 102 |
| 85-86 | 129 | 104-106 | 105 |
| 87-88 | 132 | 107-109 | 108 |
| 89-90 | 135 | 110-112 | 111 |
| 91-92 | 138 | 113-115 | 114 |
| 93-94 | 141 | 116-118 | 117 |
| 95-96 | 144 | 119-121 | 120 |
| 97-98 | 147 | 122-124 | 123 |
| 99-100 | 150 | 125-127 | 126 |
| 101-102 | 153 -use 2 SYRINGES 120mg+33mg | 128-130 | 129 |
| 103-104 | 156-use 2 SYRINGES 120mg +36mg | | |
| 105-106 | 159-use 2 SYRINGES 120mg +39mg | | |
| 107-108 | 162-use 2 SYRINGES 120mg+42mg | | |
| 109-110 | 165-use 2 SYRINGES 150mg+15mg | | |
| 111-112 | 168-use 2 SYRINGES 150mg+18mg | | |
| 113-114 | 171-use 2 SYRINGES 150mg+21mg | | |
| 115-116 | 174-use 2 SYRINGES 150mg+24mg | | |
| 117-118 | 177-use 2 SYRINGES 150mg+27mg | | |
| 119-120 | 180-use 2 SYRINGES 150mg+30mg | | |
| 121-122 | 183-use 2 SYRINGES 150mg+33mg | | |
| 123-124 | 186-use 2 SYRINGES 150mg+36mg | | |
| 125-126 | 189-use 2 SYRINGES 150mg+39mg | | |

Enoxaparin 1mg/kg twice daily (e.g. ACS treatment, patients with prosthetic valves, high-risk DVT/PE)






USE ONLY 120mg or 150mg syringes- Each Graduation is 3mg

The dose for patients with severe renal impairment (Creatinine Clearance less than 30ml/minute) is 1mg/kg ONCE DAILY

| Weight (Kg) | Syringe Dose (mg) |
|--------------------|--------------------------|
| 50-52 | 51 |
| 53-55 | 54 |
| 56-58 | 57 |
| 59-61 | 60 |
| 62-64 | 63 |
| 65-67 | 66 |
| 68-70 | 69 |
| 71-73 | 72 |
| 74-76 | 75 |
| 77-79 | 78 |
| 80-82 | 81 |
| 83-85 | 84 |
| 86-88 | 87 |
| 89-91 | 90 |
| 92-94 | 93 |
| 95-97 | 96 |
| 98-100 | 99 |
| 101-103 | 102 |
| 104-106 | 105 |
| 107-109 | 108 |
| 110-112 | 111 |
| 113-115 | 114 |
| 116-118 | 117 |
| 119-121 | 120 |
| 122-124 | 123 |
| 125-127 | 126 |
| 128-130 | 129 |
| 131-133 | 132 |
| 134-136 | 135 |
| 137-139 | 138 |
| 140-143 | 141 |

Reconstitution of Octaplex

Maintain aseptic technique throughout. The product reconstitutes quickly at room temperature to a clear or slightly opalescent solution. Use immediately after reconstitution.

| | |
|--|---|
| Allow the solvent (water for injection) and the concentrate to warm to room temperature. Remove the caps from both vials and wipe with an alcohol swab. |  |
| Remove the protective cover from the short end of the double-ended needle, making sure not to touch the exposed tip of the needle. Perforate the centre of the solvent vial with the needle held vertically. In order to withdraw the solvent completely, the needle must be introduced in such a way that it just penetrates the stopper and is visible in the vial. |  |
| Remove the protective cover from the other long end of the double-ended needle, making sure not to touch the exposed end of the needle. Hold the solvent (water for injection) vial upside down above the upright concentrate vial and quickly perforate the centre of the rubber stopper. The vacuum inside the concentrate vial will draw in the water. |  |
| Remove the double-ended needle with the empty solvent vial from the concentrate vial (place sharps in sharps container) and slowly rotate the vial until the concentrate is completely dissolved. Inspect the vial: Octaplex® dissolves quickly at room temperature to a colourless or slightly blue solution. Do not use if cloudy, has deposits or fails to dissolve completely. |  |
| After reconstitution, remove the protective cover from the filter needle (filter needle is single use only) and perforate the rubber stopper of the concentrate vial. Remove the cap of the filter needle and attach a 20ml syringe. Turn the vial with the attached syringe upside down and draw the solution into the syringe. Label the syringe (as per hospital Standard Operating Procedures regarding Preparation and Administration of an Injectable Medicine). |  |

Administration

Octaplex should only be used by a clinician following discussions with a Consultant Haematologist.

After removing the filter, administer the dose by slow intravenous injection by either I.V. bolus or via a syringe pump.

The rate of administration is initially 1 ml/minute for the first minute increase to 3ml/minute if tolerated with no significant change in observations.

If there is more than 1 vial reconstituted, the same administration line can be used for each syringe.

The dose can be put into one or more 60ml syringes for ease of use rather than several 20ml syringes (as provided in the box), as long as the infusion pump can accommodate them.

Check INR following administration (within 1 hour). If reversal is incomplete (INR>1.5) contact haematologist to discuss further management.

NB: Rate via a syringe pump: 1ml/minute = 60ml/hr, 3ml/minute = 180ml/hr

| | | |
|--------------------------------|--|---------------|
| Version No 7.0 October 2021 | Anticoagulation Current version is held on the Intranet Check with Intranet that this printed copy is the latest issue | Page 33 of 36 |
|--------------------------------|--|---------------|

APPENDIX 10

Management during invasive or surgical procedures

Table (below) summarises discontinuation advice before invasive or surgical procedures.

| Calculated creatinine clearance (ml/min) | Timing of last dose before surgery | |
|---|------------------------------------|----------------------------|
| | Standard risk of bleeding* | High risk of bleeding** |
| Dabigatran | | |
| >50m | 24 hours | 2 days |
| 30-50m | 2 days | 4 days |
| <30m | Contraindicated | |
| Rivaroxaban/Apixaban/Edoxaban | | |
| >30 | 24 hours | 2 days |
| 15-30 | 2 days | 4 days |
| <15 | Contraindicated | |

*Examples are cardiac catheterisation, colonoscopy without removal of large polyps, uncomplicated laparoscopic procedures such as cholecystectomy.

**Examples are major cardiac surgery, neurosurgery, large hernia surgery, major cancer/urologic/vascular surgery.

Device Procedures

* Standard risk includes the following device procedures: New pacemaker/ICD/CRT implant (including leadless pacemakers and subcutaneous ICDs), generator changes

** High risk includes the following device procedures: Device upgrades, lead extraction, wound revision, submuscular reburial

DOACs can usually be restarted 12-24 hours post procedure if the wound is satisfactory but individualised advice will be documented in the Cardiac Devices post procedure review document

General DOAC considerations

Conversion from Vitamin K antagonist to DOAC or vice-versa or conversion from parenteral anticoagulant to DOAC or vice-versa- refer to relevant Data Sheets

Concomitant use of antiplatelet agents: Studies with dabigatran, rivaroxaban and apixaban in patients with acute coronary syndromes, receiving combined antiplatelet therapy with aspirin and clopidogrel have generally shown a dose-dependent increase in the risk of major bleeding and any bleeding.

MONITORING

Baseline: Renal function, LFTs, FBC

On-going: Renal function at least once per year, more frequently if renal function is expected to decline.

Changes in renal function may require dose adjustments or cessation of therapy

DOACs are intensively monitored drugs (black triangle drug), as such any possible adverse effects (including any considered not to be serious) relating to treatment should be reported via the yellow card scheme (www.yellowcard.gov.uk).

Contraindications, Cautions and Adverse Effects-**SEE DATA SHEETS FOR FURTHER DETAILS**

INFORMATION TO PATIENT

Patients should be advised of benefits and risks of treatment, including signs of bleeding and of need to inform health care staff that they are taking a DOAC before any surgery is scheduled, and before taking any new medicine.

Other considerations

Dabigatran capsules are hygroscopic and should thus not be removed from their original packaging. Individual capsules should not be placed into blister packs because they will lose potency.

| | | |
|--------------------------------|--|---------------|
| Version No 7.0 October 2021 | Anticoagulation Current version is held on the Intranet Check with Intranet that this printed copy is the latest issue | Page 34 of 36 |
|--------------------------------|--|---------------|

9. Endorsed By:

| Name of Lead Clinician / Manager or Committee Chair | Position of Endorser or Name of Endorsing Committee | Date |
|---|---|------------|
| Dr Scawn | Drug & Therapeutics | 20/10/2021 |

10. Record of Changes

| Section No | Version No | Date of Change | Description of Amendment | Description of Deletion | Description of Addition | Reason |
|------------|------------|----------------|--------------------------|-------------------------|-------------------------|--------|
| | | | | | | |